Related Experiment Video
Updated: Jul 4, 2026
05:23
Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients
Published on: March 11, 2021
Dual-task interference during a functional mobility task in Parkinson's disease persists across medication states.
Colin Waltz1, Anson B Rosenfeldt1, Sumner Jones1
1Cleveland Clinic, Lerner Research Institute, Department of Biomedical Engineering, 9500 Euclid Ave, Cleveland, OH, USA.
Gait & Posture
|July 2, 2026
Summary
Antiparkinsonian medication improves functional mobility in Parkinson's disease (PD) patients, but dual-tasking significantly increases completion time, especially during gait initiation. The Safe-Gait platform effectively quantifies these mobility changes.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Rehabilitation Science
Background:
- Functional mobility is crucial for individuals with Parkinson's disease (PD).
- Objective assessment of mobility is needed to evaluate treatment efficacy.
- The Safe-Gait platform integrates multiple functional mobility tasks.
Purpose of the Study:
- To determine the effects of antiparkinsonian medication and dual-tasking on mobility in PD.
- To quantify overall and phase-specific temporal measures of functional mobility.
- To evaluate the sensitivity of the Safe-Gait platform in PD.
Main Methods:
- Thirty-two PD participants completed the Safe-Gait test under single-task (ST) and dual-task (DT) conditions.
- Testing was performed ON- and OFF-antiparkinsonian medication.
- Completion time and phase-specific times were analyzed using linear mixed models.
Main Results:
- Overall completion time was 6.2% longer OFF-medication compared to ON-medication.
- Dual-tasking increased completion time by 13% compared to single-tasking.
- Gait initiation showed the smallest medication effect (2%) but the largest dual-task interference (21%).
Conclusions:
- Dopaminergic medication improves overall functional mobility in PD but does not mitigate dual-task interference.
- Gait initiation is highly sensitive to cognitive-motor demands, showing minimal medication response and maximal dual-task interference.
- The Safe-Gait platform is a sensitive and ecologically valid tool for assessing functional mobility in PD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...